BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38852945)

  • 21. Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.
    Subbiah V; Berry J; Roxas M; Guha-Thakurta N; Subbiah IM; Ali SM; McMahon C; Miller V; Cascone T; Pai S; Tang Z; Heymach JV
    Lung Cancer; 2015 Jul; 89(1):76-9. PubMed ID: 25982012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RET in breast cancer: pathogenic implications and mechanisms of drug resistance.
    Lo Nigro C; Rusmini M; Ceccherini I
    Cancer Drug Resist; 2019; 2(4):1136-1152. PubMed ID: 35582269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of RET is associated with Oestrogen receptor expression but lacks prognostic significance in breast cancer.
    Mechera R; Soysal SD; Piscuoglio S; Ng CKY; Zeindler J; Mujagic E; Däster S; Glauser P; Hoffmann H; Kilic E; Droeser RA; Weber WP; Muenst S
    BMC Cancer; 2019 Jan; 19(1):41. PubMed ID: 30621641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RET signaling pathway and RET inhibitors in human cancer.
    Regua AT; Najjar M; Lo HW
    Front Oncol; 2022; 12():932353. PubMed ID: 35957881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective RET kinase inhibition for patients with RET-altered cancers.
    Subbiah V; Velcheti V; Tuch BB; Ebata K; Busaidy NL; Cabanillas ME; Wirth LJ; Stock S; Smith S; Lauriault V; Corsi-Travali S; Henry D; Burkard M; Hamor R; Bouhana K; Winski S; Wallace RD; Hartley D; Rhodes S; Reddy M; Brandhuber BJ; Andrews S; Rothenberg SM; Drilon A
    Ann Oncol; 2018 Aug; 29(8):1869-1876. PubMed ID: 29912274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gain of HIF1 Activity and Loss of miRNA
    Wyss CB; Duffey N; Peyvandi S; Barras D; Martinez Usatorre A; Coquoz O; Romero P; Delorenzi M; Lorusso G; Rüegg C
    Cancer Res; 2021 Feb; 81(3):594-605. PubMed ID: 33526470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gamma Knife surgery for metastatic brain tumors from primary breast cancer: treatment indication based on number of tumors and breast cancer phenotype.
    Matsunaga S; Shuto T; Kawahara N; Suenaga J; Inomori S; Fujino H
    J Neurosurg; 2010 Dec; 113 Suppl():65-72. PubMed ID: 21121788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ret Receptor Has Distinct Alterations and Functions in Breast Cancer.
    Gattelli A; Hynes NE; Schor IE; Vallone SA
    J Mammary Gland Biol Neoplasia; 2020 Mar; 25(1):13-26. PubMed ID: 32080788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations.
    Wang H; Wang Z; Zhang G; Zhang M; Zhang X; Li H; Zheng X; Ma Z
    Cancer Med; 2020 Jan; 9(2):487-495. PubMed ID: 31769228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases.
    Priedigkeit N; Hartmaier RJ; Chen Y; Vareslija D; Basudan A; Watters RJ; Thomas R; Leone JP; Lucas PC; Bhargava R; Hamilton RL; Chmielecki J; Puhalla SL; Davidson NE; Oesterreich S; Brufsky AM; Young L; Lee AV
    JAMA Oncol; 2017 May; 3(5):666-671. PubMed ID: 27926948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance.
    Plaza-Menacho I; Morandi A; Robertson D; Pancholi S; Drury S; Dowsett M; Martin LA; Isacke CM
    Oncogene; 2010 Aug; 29(33):4648-57. PubMed ID: 20531297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic and epigenetic factors affect RET gene expression in breast cancer cell lines and influence survival in patients.
    Griseri P; Garrone O; Lo Sardo A; Monteverde M; Rusmini M; Tonissi F; Merlano M; Bruzzi P; Lo Nigro C; Ceccherini I
    Oncotarget; 2016 May; 7(18):26465-79. PubMed ID: 27034161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts.
    Andreucci E; Francica P; Fearns A; Martin LA; Chiarugi P; Isacke CM; Morandi A
    Oncotarget; 2016 Dec; 7(49):80543-80553. PubMed ID: 27602955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.
    Spitschak A; Meier C; Kowtharapu B; Engelmann D; Pützer BM
    Mol Cancer; 2017 Jan; 16(1):24. PubMed ID: 28122586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TGF-β stimulates Pyk2 expression as part of an epithelial-mesenchymal transition program required for metastatic outgrowth of breast cancer.
    Wendt MK; Schiemann BJ; Parvani JG; Lee YH; Kang Y; Schiemann WP
    Oncogene; 2013 Apr; 32(16):2005-15. PubMed ID: 22710711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma.
    Wiens AL; Martin SE; Bertsch EC; Vance GH; Stohler RA; Cheng L; Badve S; Hattab EM
    Arch Pathol Lab Med; 2014 Feb; 138(2):175-81. PubMed ID: 24476516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting RET Kinase in Neuroendocrine Prostate Cancer.
    VanDeusen HR; Ramroop JR; Morel KL; Bae SY; Sheahan AV; Sychev Z; Lau NA; Cheng LC; Tan VM; Li Z; Petersen A; Lee JK; Park JW; Yang R; Hwang JH; Coleman I; Witte ON; Morrissey C; Corey E; Nelson PS; Ellis L; Drake JM
    Mol Cancer Res; 2020 Aug; 18(8):1176-1188. PubMed ID: 32461304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Rearranged During Transfection (RET) Gene Rearrangements in Primary Versus Metastatic Non-Small Cell Lung Cancer (NSCLC).
    Zhang Q; Xu C; Wang W; Wu M; Zhu Y; Zhuang W; Du K; Huang Y; Chen Y; Wu B
    Med Sci Monit; 2018 Nov; 24():8207-8212. PubMed ID: 30429449
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting Brain-Adaptive Cancer Stem Cells Prohibits Brain Metastatic Colonization of Triple-Negative Breast Cancer.
    Ren D; Zhu X; Kong R; Zhao Z; Sheng J; Wang J; Xu X; Liu J; Cui K; Zhang XH; Zhao H; Wong STC
    Cancer Res; 2018 Apr; 78(8):2052-2064. PubMed ID: 29567857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer.
    Brown WS; Tan L; Smith A; Gray NS; Wendt MK
    Mol Cancer Ther; 2016 Sep; 15(9):2096-106. PubMed ID: 27371729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.